Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase (GALNS), an enzyme that degrades keratan sulfate (KS). Currently no therapy for MPS IVA is available. We produced recombinant human (rh)GALNS as a potential enzyme replacement therapy for MPS IVA. Chinese hamster ovary cells stably overexpressing GALNS and sulfatase modifying factor-1 were used to produce active ( approximately 2 U/mg) and pure (>or=97%) rhGALNS. The recombinant enzyme was phosphorylated and was dose-dependently taken up by mannose-6-phosphate receptor (K(uptake) = 2.5 nM), thereby restoring enzyme activity in MPS IVA fibroblasts. In the absence of an animal model with a skeletal phenotype, we established chondrocytes isolated from two MPS IVA patients as a disease model in vitro. MPS IVA chondrocyte GALNS activity was not detectable and the cells exhibited KS storage up to 11-fold higher than unaffected chondrocytes. MPS IVA chondrocytes internalized rhGALNS into lysosomes, resulting in normalization of enzyme activity and decrease in KS storage. rhGALNS treatment also modulated gene expression, increasing expression of chondrogenic genes Collagen II, Collagen X, Aggrecan and Sox9 and decreasing abnormal expression of Collagen I. Intravenous administration of rhGALNS resulted in biodistribution throughout all layers of the heart valve and the entire thickness of the growth plate in wild-type mice. We show that enzyme replacement therapy with recombinant human GALNS results in clearance of keratan sulfate accumulation, and that such treatment ameliorates aberrant gene expression in human chondrocytes in vitro. Penetration of the therapeutic enzyme throughout poorly vascularized, but clinically relevant tissues, including growth plate cartilage and heart valve, as well as macrophages and hepatocytes in wild-type mouse, further supports development of rhGALNS as enzyme replacement therapy for MPS IVA.
Dvorak-Ewell
Melita
M
BioMarin Pharmaceutical Inc., Novato, California, United States of America.
Wendt
Dan
D
Hague
Chuck
C
Christianson
Terri
T
Koppaka
Vish
V
Crippen
Danielle
D
Kakkis
Emil
E
Vellard
Michel
M
D000818:Animals; D001692:Biological Transport; D002356:Cartilage / Q000378:metabolism*; D002417:Cattle; D019902:Chondrocytes / Q000378:metabolism / Q000473:pathology; D002811:Chondroitinsulfatases / Q000302:isolation & purification / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D056947:Enzyme Replacement Therapy / Q000379:methods*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006132:Growth Plate / Q000378:metabolism; D006351:Heart Valves / Q000378:metabolism; D006801:Humans; D007632:Keratan Sulfate / Q000378:metabolism; D008099:Liver / Q000473:pathology; D008247:Lysosomes / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D009085:Mucopolysaccharidosis IV / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use
D011994:Recombinant Proteins; D007632:Keratan Sulfate; D002811:Chondroitinsulfatases; C102295:GALNS protein, human
Blood. 1995 Dec 15;86(12):4645-9
8541556
Arch Dis Child. 1990 Jul;65(7):746-9
2117422
Mol Genet Metab. 2007 Jul;91(3):251-8
17498992
FEBS Lett. 1989 Dec 4;258(2):195-8
2599085
J Thorac Cardiovasc Surg. 1974 Sep;68(3):352-60
4850482
J Inherit Metab Dis. 2001;24 Suppl 2:47-51; discussion 45-6
11758678
Mol Vis. 2008 Feb 09;14:308-17
18334944
Nat Protoc. 2008;3(8):1253-60
18714293
Clin Chim Acta. 1990 Feb 28;187(2):131-9
2107987
J Inherit Metab Dis. 2007 Apr;30(2):165-74
17347914
Mol Genet Metab. 2009 Jul;97(3):196-201
19394256
Acta Neuropathol. 2008 Feb;115(2):159-74
17924126
Pathology. 1986 Apr;18(2):217-21
3093960
Gene. 2003 Oct 16;316:47-56
14563551
J Bone Joint Surg Am. 1962 Mar;44-A:295-306
14036761
Biochem J. 1995 Oct 1;311 ( Pt 1):333-9
7575473
Mol Ther. 2010 Jun;18(6):1094-102
20332769
Cell. 2003 May 16;113(4):445-56
12757706
Acta Paediatr Scand. 1982 May;71(3):353-63
6814174
Matrix Biol. 1999 Aug;18(4):381-90
10517185
Mol Genet Metab. 2007 May;91(1):69-78
17336563
Johns Hopkins Med J. 1975 Oct;137(4):176-83
810613
Eur J Pediatr. 1998 Jul;157(7):534-8
9686810
Am J Med Genet Suppl. 1987;3:243-55
2835968
Clin Orthop Relat Res. 1986 Jul;(208):119-25
3522019
Osteoarthritis Cartilage. 2007 Nov;15(11):1311-7
17548214
Hum Mol Genet. 2008 Mar 15;17(6):815-24
18056156
Hum Mol Genet. 2005 Nov 15;14(22):3321-35
16219627
Clin Chim Acta. 1979 Apr 16;93(2):207-13
156097
Expert Opin Investig Drugs. 2002 May;11(5):675-85
11996648
FASEB J. 1997 Mar;11(4):227-33
9068611
Biochem J. 2007 Apr 15;403(2):305-12
17206939
J Inherit Metab Dis. 1996;19(3):357-65
8803780
Glycobiology. 2004 Jul;14(7):621-33
15044391
Tohoku J Exp Med. 1983 Mar;139(3):321-6
6222514
J Biochem. 1991 Dec;110(6):965-70
1794986
Virchows Arch A Pathol Anat Histol. 1978 Aug 4;379(1):1-10
150685
J Bone Joint Surg Br. 1991 Sep;73(5):851-8
1910048
Bone Marrow Transplant. 2003 Feb;31(4):229-39
12621457
J Biol Chem. 1989 Jul 25;264(21):12115-8
2545698
Best Pract Res Clin Rheumatol. 2006 Oct;20(5):1003-25
16980220
J Biol Chem. 1995 Jan 27;270(4):1747-53
7829510
Hum Mol Genet. 2003 Dec 15;12(24):3349-58
14583446
J Orthop Res. 2000 Nov;18(6):882-90
11192247